Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cosmos Health Inc. filings document the public-company record of a Nevada healthcare issuer with common stock listed on the Nasdaq Capital Market under COSM. Recent Form 8-K reports cover operating results, Regulation FD disclosures, Nasdaq minimum-bid-price compliance matters, board appointments, annual-meeting voting results and capital-structure proposals involving common stock and blank-check preferred stock.
The filing record also includes a Form 12b-25 notice for a delayed annual report and disclosures tied to business performance across contract manufacturing, wholesale distribution, proprietary nutraceutical brands and research and development. These documents address governance, listing status, share authorization, financial reporting timing and the company's operating subsidiaries and product portfolio.
Cosmos Health Inc. files its annual report outlining a diversified healthcare business spanning generic drugs, proprietary nutraceuticals, biocides, medical devices and telehealth. The company operates GMP- and EMA‑certified manufacturing in Greece, wholesale distribution across Europe and the UK, and a growing Sky Premium Life nutraceutical brand.
Cosmos highlights an innovation‑focused pipeline, including CCX0722, an obesity and weight‑management hydrogel product targeted for a third or fourth quarter 2026 market launch, and several oncology programs backed by WIPO patents and exclusive licenses. It also acquired the AI‑driven Cloudscreen drug‑repurposing platform and filed multiple patent applications for neurological and hematologic indications.
The report notes 2025 inventory of $5.8 million, geographically concentrated revenues in Greece, and a workforce of 163 employees. During 2025, Cosmos used an at‑the‑market share program, equity compensation plans and debt‑for‑equity exchanges to raise capital, settle obligations and fund R&D initiatives and growth strategy.
Cosmos Health Inc. disclosure shows Andreas Bovopoulos beneficially owns 3,733,412 shares of common stock, representing 9.974% of the class. The percentage is calculated against approximately 37,432,522 shares outstanding as of February 24, 2026.
The filing states Mr. Bovopoulos has sole voting power and sole dispositive power over the 3,733,412 shares. This entry appears as an amendment to a prior Schedule 13G/A and records beneficial ownership at the disclosed level.
Cosmos Health Inc. CEO, director and 10% owner Grigorios Siokas acquired 388,532 shares of common stock on February 12, 2026. The shares were issued at $0.3732 per share in exchange for $145,000 of debt the company owed to him. Following this transaction, he directly owns 8,861,914 shares of Cosmos Health common stock.
Cosmos Health Inc. Chief Executive Officer, director and 10% owner Grigorios Siokas acquired 291,262 shares of common stock on February 11, 2026. The shares were obtained at $0.4120 per share in exchange for $120,000 of debt the company owed to him under a debt exchange agreement.
Following this transaction, Mr. Siokas directly beneficially owns 8,473,382 shares of Cosmos Health common stock.
Cosmos Health Inc. filed a Form 4 showing that CEO, director and 10% owner Grigorios Siokas acquired additional common shares through a debt-for-equity exchange. On January 23, 2026, he obtained 90,325 shares of common stock at $0.4982 per share, representing the fair market value that day, in exchange for $45,000 of debt the company owed him under a Debt Exchange Agreement. Following this transaction, he directly holds 8,182,120 common shares.
Cosmos Health Inc.'s Chief Executive Officer, director, and 10% owner Grigorios Siokas acquired additional common shares of the company through a debt exchange. On January 20, 2026, he obtained 353,321 shares of common stock at $0.4953 per share, described as the fair market value on that date. The shares were issued under a Debt Exchange Agreement in which $175,000 of debt the company owed to Mr. Siokas was exchanged for equity.
Following this transaction, Mr. Siokas beneficially owns 8,091,795 shares of Cosmos Health common stock in direct ownership. The filing characterizes the transaction with code "P" and notes that these shares are classified as Exchange Shares under the terms of the Debt Exchange Agreement.
Cosmos Health Inc.'s Chief Executive Officer, director and 10% owner Grigorios Siokas reported acquiring 493,495 shares of common stock on January 14, 2026. The shares were obtained at $0.4458 per share, described as the fair market value on that date, through a debt exchange agreement with the company.
Under this agreement, Mr. Siokas exchanged $220,000 of debt that the company owed him for these "Exchange Shares". Following the transaction, he beneficially owned 7,738,474 shares of Cosmos Health common stock in direct ownership.
Cosmos Health Inc. insider filing shows its CEO and 10% owner, Grigorios Siokas, acquiring 113,185 shares of common stock on January 12, 2026. The shares were obtained at $0.5036 per share under a Debt Exchange Agreement, using $57,000 of debt the company owed to him as payment instead of cash. After this transaction, he beneficially owns 7,244,979 common shares directly.
Cosmos Health Inc. insider transaction: Chief Executive Officer, director, and 10% owner Grigorios Siokas acquired 156,190 shares of Common Stock on January 8, 2026. The shares were obtained at $0.5186 per share pursuant to a Debt Exchange Agreement, in which $81,000 of debt that the company owed to Mr. Siokas was exchanged for stock at the fair market value on that date. Following this transaction, he beneficially owned 7,131,794 shares of Common Stock, held directly.